Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

BACKGROUND: Fibrodysplasia Ossificans Progressiva (FOP) is a genetic, progressive and devastating disease characterized by severe heterotopic ossification (HO), loss of mobility and early death. There are no FDA approved medications. The STOPFOP team identified AZD0530 (saracatinib) as a potent inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Smilde, Bernard J., Stockklausner, Clemens, Keen, Richard, Whittaker, Andrew, Bullock, Alex N., von Delft, Annette, van Schoor, Natasja M., Yu, Paul B., Eekhoff, E. Marelise W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156821/
https://www.ncbi.nlm.nih.gov/pubmed/35650602
http://dx.doi.org/10.1186/s12891-022-05471-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156821/
https://www.ncbi.nlm.nih.gov/pubmed/35650602
http://dx.doi.org/10.1186/s12891-022-05471-x

Ejemplares similares